• Guillaume HABAULT posted an update in the hub Biowebspin 1 year, 5 months ago

    Cross-border R&D alliance networks: an empirical study of the umbilical cord blood banking industry in emerging markets - Biowebspin | Biowebspin

    Activity 474816 illustration

    The concept of the cross-border collaboration network has been recognised as a useful way to obtain external R&D knowledge resources in the biotechnology industry. Drawing on social capital theory, this study explores how two types of network position (centrality and structural holes) and cross-border collaborative ties affect the cross-border R&D…[Read more]

  • Guillaume HABAULT posted an update in the hub Biowebspin 1 year, 5 months ago

    Does it pay to stand on the shoulders of giants? An analysis of the inventions of star inventors in the biotechnology sector - Biowebspin | Biowebspin

    Activity 474654 illustration

    Previous research has highlighted the importance of star inventors for invention success and firm performance. However, we have limited knowledge regarding the indirect influence of star inventors on knowledge generation and how the ideas of star inventors influence subsequent invention performance. Therefore, this study uses biotechnology patents…[Read more]

  • Guillaume HABAULT posted an update in the hub Biowebspin 1 year, 5 months ago

    Factors stimulating open innovation - Biowebspin | Biowebspin

    Activity 474416 illustration

    The term innovation which is about the novelty on products, processes, services, technologies, on strategies or organizational structures is important for companies to stay in the competition and run their businesses well to gain both financial and organizational achievements. By the changing and globalizing world, innovation may require some…[Read more]

  • Guillaume HABAULT posted an update in the hub Biowebspin 1 year, 5 months ago

    Learning from successes and failures in pharmaceutical R&D - Biowebspin | Biowebspin

    Activity 473886 illustration

    In this paper, we build a cumulative innovation model to understand the role of both success and failure in the learning dynamics that characterize pharmaceutical R&D. We test the prediction of our model by means of a unique dataset that combines patent information with R&D projects, thus distinguishing patents related to successfully marketed…[Read more]

  • Guillaume HABAULT posted an update in the hub Biowebspin 1 year, 5 months ago

    What Finance Can Learn from Biopharma Industry: A Transfer of Innovation Models - Biowebspin | Biowebspin

    Activity 473496 illustration

    The financial sector is living a profound crisis in order to keep pace with the continuous technological breakthroughs that come out daily, while other sectors seem to be historically more growth-by-innovation-based (e.g., the pharma/biotech sector). This work focuses on an interdisciplinary approach to innovation, and on insights that the banking…[Read more]

  • Guillaume HABAULT posted an update in the hub Biowebspin 1 year, 5 months ago

    Potential and Challenges for Start-Ups in Japan’s Biotech Industry - Biowebspin | Biowebspin

    Activity 473131 illustration

    Although Japan has both a globally rare national M&Ated healthcare program and one of the most extensive life science research capabilities in the world, there is a risk of their divergence due to Japan’s aging citizenry and the domestic pharmaceutical industry. In order to bridge the gap between the research ndings and the healthcare welfare w…[Read more]

  • Guillaume HABAULT posted an update in the hub Biowebspin 1 year, 6 months ago

    Incentives for Starting Small Companies Focused on Rare and Neglected Diseases - Biowebspin | Biowebspin

    Activity 472315 illustration

    Starting biotech or pharmaceutical companies is traditionally thought to be based around a scientist, their technology platform or a clinical candidate spun out from another company. Between us we have taken a different approach and formed two small early stage companies after initially leveraging the perspective of a parent with a child with a…[Read more]

  • Guillaume HABAULT posted an update in the hub Biowebspin 1 year, 6 months ago

    Open Innovation and Business Model: A Brazilian Company Case Study - Biowebspin | Biowebspin

    Activity 472277 illustration

    Open Innovation is increasingly being introduced in international and national organizations for the creation of value. Open innovation is a practical tool, requiring new strategies and decisions from managers for the exploitation of innovative activities. The basic question that this study seeks to answer is linked to the practice of open…[Read more]

  • Guillaume HABAULT posted an update in the hub Biowebspin 1 year, 6 months ago

    Strategic investments in non-communicable diseases (NCD) research in Africa: the GSK Africa NCD Open Lab - Biowebspin | Biowebspin

    Activity 472014 illustration

    In March 2014, GSK announced a number of new strategic investments in Africa. One of these included investment of up to 25 million Pounds Sterling (£25 million) to create the world’s first R&D Open Lab to increase understanding of non-communicable diseases (NCDs) in Africa. The vision is to create a new global R&D effort with GSK working in pa…[Read more]

  • Guillaume HABAULT posted an update in the hub Biowebspin 1 year, 6 months ago

    Scientists Collaborating with Industry: An Exploration of Industry Engagement Types - Biowebspin | Biowebspin

    Activity 470795 illustration

    Involvement of researchers in industry is undeniably beneficial for companies. It drives innovations, patents, licenses and ultimately profits. However, participation of scientists in industry is still scarce. With the aim of emphasizing the benefits of scientific involvement in industry, we conducted a comprehensive exploration of various types…[Read more]

  • Guillaume HABAULT posted an update in the hub Biowebspin 1 year, 7 months ago

    Industry–academia collaborations for biomarkers | Biowebspin

    Activity 470131 illustration

    Several types of collaboration are being pursued to identify, validate and apply new biomarkers. Here, we highlight examples of such initiatives and discuss the challenges, approaches to address these challenges and key factors for success.

    Read the full article at http://www.biowebspin.com/industry-academia-collaborations-for-biomarkers/

  • Guillaume HABAULT posted an update in the hub Biowebspin 1 year, 7 months ago

    Open Innovation in Health Care | Biowebspin

    Activity 469936 illustration

    Traditionally, the dominant form of innovation required that firms generate ideas internally and subsequently develop and market resulting products themselves. Yet, this mode of innovation is not always the best solution, because a single firm might not possess all relevant knowledge or capabilities. The open innovation concept, therefore,…[Read more]

  • Guillaume HABAULT posted an update in the hub Biowebspin 1 year, 7 months ago

    Open innovation and intellectual property: time for a reboot? | Biowebspin

    Activity 469729 illustration

    Biowebspin, November 23rd, 2015 Open innovation and intellectual property: time for a reboot? by Duncan B. Judd in Drug Discovery Today, 2013

    Read the full article at http://www.biowebspin.com/open-innovation-and-intellectual-property-time-for-a-reboot/

  • Guillaume HABAULT posted an update in the hub Biowebspin 1 year, 7 months ago

    A crowd-sourcing approach for the construction of species-specific cell signaling networks | Biowebspin

    Activity 469478 illustration

    Motivation: Animal models are important tools in drug discovery and for understanding human biology in general. However, many drugs that initially show promising results in rodents fail in later stages of clinical trials. Understanding the commonalities and differences between human and rat cell signaling networks can lead to better experimental…[Read more]

  • Guillaume HABAULT posted an update in the hub Biowebspin 1 year, 7 months ago

    A Crowdsourcing Evaluation of the NIH Chemical Probes | Biowebspin

    Activity 469370 illustration

    Between 2004 and 2008, the NIH molecular libraries and imaging initiative (MLI) pilot phase funded ten high-throughput Screening Centers, resulting in the deposition of 691 assays into PubChem and the nomination of 64 chemical probes. We crowdsourced the MLI output to 11 experts, who expressed medium or high levels of confidence in 48 of these 64…[Read more]

  • Guillaume HABAULT posted an update in the hub Biowebspin 1 year, 7 months ago

    Fueling Open-Source Drug Discovery: 177 Small-Molecule Leads against Tuberculosis | Biowebspin

    Activity 469201 illustration

    With the aim of fuelling open-source, translational, early-stage drug discovery activities, the results of the recently completed antimycobacterial phenotypic screening campaign against Mycobacterium bovis BCG with hit confirmation in M. tuberculosis H37Rv were made publicly accessible. A set of 177 potent non-cytotoxic H37Rv hits was identified…[Read more]

  • Guillaume HABAULT posted an update in the hub Biowebspin 1 year, 7 months ago

    Over 1.8 million people were diagnosed with lung cancer in 2012, making it the most common form of cancer worldwide. It is the leading cause of cancer deaths in men, the second in women and 1.59 million people die annually from the disease. Although there have been significant advances in imaging to detect the presence of tumours and testing…[Read more]

  • Guillaume HABAULT posted an update in the hub Biowebspin 1 year, 7 months ago

    Key drivers of biomedical innovation in cancer drug discovery | Biowebspin

    Activity 468429 illustration

    Discovery and translational research has led to the identification of a series of “cancer drivers”—genes that, when mutated or otherwise misregulated, can drive malignancy. An increasing number of drugs that directly target such drivers have demonstrated activity in clinical trials and are shaping a new landscape for molecularly targeted cance…[Read more]

  • Guillaume HABAULT posted an update in the hub Biowebspin 1 year, 7 months ago

    Opening the door to innovation | Biowebspin

    Activity 467659 illustration

    Open innovation is the new buzz, with initiatives popping up left and right. Here, we give a personal perspective on a very successful, knowledge-driven innovation initiated in an academia- industry alliance, which culminated in technology platforms that enable the generation of therapeutic antibodies with novel properties. To start, we provide a…[Read more]

  • Guillaume HABAULT posted an update in the hub Biowebspin 1 year, 7 months ago

    Timothy Grese is speaking about open innovation at Eli Lilly | Biowebspin

    Activity 466976 illustration

    Chief Scientific Officer, Lead Generation, and External Innovation, Discovery Chemistry Research and Technology at Eli Lilly.

    Read the full article at http://www.biowebspin.com/timothy-grese-eli-lilly-about-open-innovation/

  • Load More